Panelists discuss how ADA recommendations emphasize treating diabetes as part of overlapping conditions requiring cardiovascular and kidney protection, moving beyond just glycemic control to comprehensive care that addresses the whole person.
The DiRECT Trial and Weight Management Programs
The DiRECT trial conducted in the UK was inspired by patients' most common question: "Is diabetes reversible?" This landmark study incorporated the Counterweight Program into primary care settings, demonstrating that structured weight management interventions can lead to diabetes remission. After 12 months, approximately 46% of relatively newly diagnosed diabetes patients who were not on insulin achieved hemoglobin A1c levels below 6.5%, technically achieving remission.
The program involved meal replacements with liquid diets for up to 20 weeks, gradual food reintroduction, and frequent counseling support. Patients who lost 15-20% of their starting weight were most likely to maintain remission. However, the challenge of maintaining weight loss became evident as remission rates decreased to approximately 12-15% by five years, highlighting the difficulty of sustained lifestyle changes.
The trial proves that diabetes remission is possible through lifestyle interventions, but successful programs must be accessible, cost-effective, and capable of re-engaging patients throughout their lives. The research emphasizes the importance of early intervention for weight reduction to improve metabolic parameters and potentially achieve diabetes remission, while acknowledging the ongoing challenge of long-term weight maintenance.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More